PBAC's latest decision on Dolutegravir/rilpivirine: Recommended with restriction (2018). Considered for Treatment of virologically suppressed HIV-infected patients. The fixed dose combination is indicated for use in virologically suppressed patients switching from current antiretroviral therapy.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2018
Submissions
1
2018 → 2018
Eligible population
Virologically suppressed HIV-infected patients who are stable and virologically suppressed on previous HIV treatment regimen for at least 6 months prior to treatment initiation
Therapy area
Infectious disease
Line of therapy
Any
Evidence base
RCT
Primary endpoint
Virological success (HIV-1 RNA <50 c/mL)
Pivotal trial size
1,024 patients
Key trials
Study 201676, SWORD 1, SWORD 2, DEXA
Comparator
dolutegravir 50mg plus rilpivirine 25mg taken concomitantly (DTG+RPV)
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis conducted; no ICER calculated as this was a cost-minimisation comparison against individual components